Biomarker tests for decision-making on chemotherapy for breast cancer: No evidence of transferability
Following a benefit assessment in 2016 and an addendum in 2018, the German Institute for Quality and Efficiency in Health Care (IQWiG) has again examined biomarker-based tests for women with primary breast cancer. These tests aim to identify patients who could omit adjuvant chemotherapy because they have a low risk of recurrence, i.e. they can…
Details